International Urology and Nephrology

, Volume 50, Issue 7, pp 1271–1275 | Cite as

Calcimimetics versus parathyroidectomy: What is preferable?

  • M. Rroji
  • G. Spasovski
Nephrology - Review


Secondary hyperparathyroidism (SHPT) is common among patients with end-stage renal disease (ESRD). SHPT is associated with high-turnover bone disease, interstitial and vascular calcifications, cardiovascular morbidity and mortality. The pharmacological management of SHPT has progressed in recent years. The introduction of targeted therapies, such as selective vitamin D receptors activators and calcium-sensing receptor modulators, offers an increased opportunity to adequately control elevated parathyroid hormone (PTH), especially in patients with chronic kidney disease under dialysis treatment. Calcimimetic medications such as cinacalcet negatively feedback on the parathyroid glands and do not have the consequences of calcium augmentation. However, there are no randomised, prospective data that demonstrate improved quality of life, improvement in anemia, reduction in phosphate binders, reduction in use of vitamin D analogs, or reduction in mortality. Literature supports cinacalcet therapy to improve patient outcomes, especially with regard to vascular calcifications and presumably the very lethal condition of calciphylaxis. However, cinacalcet is administered orally and has been associated with gastrointestinal intolerance along with hypocalcemia. In addition, poor adherence has been observed among dialysis patients self-administering oral cinacalcet. On the other hand, successful surgical parathyroidectomy (sPTX) can yield a dramatic reduction in PTH level and clinical symptoms. The advanced pharmacological treatments of SHPT often obviate parathyroidectomy; however, some researchers have reported that sPTX may be more cost-effective than cinacalcet in some patients with ESRD and suffering uncontrolled SHPT.


Dialysis Secondary hyperparathyroidism Parathyroidectomy Calcimimetic 


Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants performed by any of the authors.


  1. 1.
    Moe S, Drüeke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, Eknoyan G (2006) Kidney disease: improving global outcomes (KDIGO). Definition, evaluation, and classification of renal osteodystrophy: a position statement from kidney disease: improving global outcomes (KDIGO). Kidney Int 69(11):1945–1953CrossRefPubMedGoogle Scholar
  2. 2.
    Cunningham J, Sprague SM, Cannata-Andia J, Coco M, Cohen-Solal M, Fitzpatrick L, Goltzmann D, Lafage-Proust MH, Leonard M, Ott S, Rodriguez M, Stehman-Breen C, Stern P, Weisinger J, Osteoporosis Work Group (2004) Osteoporosis in chronic kidney disease. Am J Kidney Dis 43:566–571CrossRefPubMedGoogle Scholar
  3. 3.
    Torres PA, De Broe M (2012) Calcium-sensing receptor, calcimimetics, and cardiovascular calcifications in chronic kidney disease. Kidney Int 82:19–25CrossRefPubMedGoogle Scholar
  4. 4.
    Block GA, Klassen PS, Lazarus JM et al (2004) Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 15:2208–2218CrossRefPubMedGoogle Scholar
  5. 5.
    Ganesh SK, Stack AG, Levin NW et al (2001) Association of elevated serum PO(4), Ca × PO(4) product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 12:2131–2138PubMedGoogle Scholar
  6. 6.
    KDIGO (2012) Clinical practice guideline for the evaluation and management of chronic kidney disease, vol 3(1), pp 1–150, January 2013Google Scholar
  7. 7.
    Uhlig K, Berns JS, Kestenbaum B et al (2010) KDOQI U.S. commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Am J Kidney Dis 55:773–799CrossRefPubMedGoogle Scholar
  8. 8.
    National Kidney Foundation (2003) K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 42:S1Google Scholar
  9. 9.
    Goodman WG, Frazao JM, Goodkin DA et al (2000) A calcimimetic agent lowers plasma parathyroid hormone levels in patients with secondary hyperparathyroidism. Kidney Int 58(1):436–445CrossRefPubMedGoogle Scholar
  10. 10.
    Nemeth EF, Bennett SA (1998) Tricking the parathyroid gland with novel calcimimetic agents. Nephrol Dial Transpl 13:1923–1925CrossRefGoogle Scholar
  11. 11.
    Moe SM, Chertow GM, Coburn JW et al (2005) Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int 67(2):760–771CrossRefPubMedGoogle Scholar
  12. 12.
    Messa P, Macário F, Yaqoob M et al (2008) The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 3(1):36–45CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Sprague SM, Evenepoel P, Curzi MP et al (2009) Simultaneous control of PTH and CaxP Is sustained over three years of treatment with cinacalcet HCl. Clin J Am Soc Nephrol 4(9):1465–1476CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Arenas MD, Alvarez-Ude F, Gil MT et al (2007) Implementation of ‘K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease’ after the introduction of cinacalcet in a population of patients on chronic haemodialysis. Nephrol Dial Transpl 22(6):1639–1644CrossRefGoogle Scholar
  15. 15.
    Fishbane S, Shapiro WB, Corry DB et al (2008) Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 3(6):1718–1725CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Urena-Torres P, Bridges I, Christiano C et al (2013) Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism. Nephrol Dial Transpl 28(5):1241–1254CrossRefGoogle Scholar
  17. 17.
    Behets GJ, Spasovski G, D’Haese PC et al (2015) Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism. Kidney Int 87:846–856CrossRefPubMedGoogle Scholar
  18. 18.
    Ketteler M, Block GA, Evenepoel P et al (2017) Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (ckd-mbd) guideline update: what’s changed and why it matters. Kidney Int 92:26–36CrossRefPubMedGoogle Scholar
  19. 19.
    Navaneethan SD, Palmer SC, Vecchio M et al (2011) Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev. PubMedCrossRefGoogle Scholar
  20. 20.
    Palmer SC, McGregor DO, Macaskill P et al (2007) Meta-analysis: vitamin D compounds in chronic kidney disease. Ann Intern Med 147(12):840–853CrossRefPubMedGoogle Scholar
  21. 21.
    Trial Investigators EVOLVE, Chertow GM, Block GA, Parfrey PS et al (2012) Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 367(26):2482–2494CrossRefGoogle Scholar
  22. 22.
    Carney EF (2013) Chronic kidney disease: no significant effect of cinacalcet on cardiovascular outcomes in patients undergoing dialysis–EVOLVE results. Nat Rev Nephrol 9(1):4. (Epub 2012 Nov 20)CrossRefPubMedGoogle Scholar
  23. 23.
    Vervloet MG, du Buf-Vereijken PW, Potter van Loon BJ et al (2013) Cinacalcet for secondary hyperparathyroidism: from improved mineral levels to improved mortality? Neth J Med 71(7):348–354PubMedGoogle Scholar
  24. 24.
    Locatelli F, Messa P, Bellasi A et al (2013) What can we learn from a statistically inconclusive trial? Consensus conference on the EVOLVE study results. G Ital Nefrol 30(5):pii:gin/30.5.4Google Scholar
  25. 25.
    Wheeler DC et al (2014) Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. J Am Heart Assoc 3(6):e001363. CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Belozeroff V, Chertow GM, Graham CN (2015) Economic evaluation of cinacalcet in the United States: the EVOLVE trial. Value Health 18(8):1079–1087CrossRefPubMedGoogle Scholar
  27. 27.
    Fukuma Sh, Akizawa T, Fukuhara Sh et al (2013) Impact of cinacalcet introduction on MBD management: the MBD-5D study in Japan. Kidney Int Suppl (2011) 3(5):436–441CrossRefPubMedCentralGoogle Scholar
  28. 28.
    Akizawa T, Kurita N, Fukuhara Sh (2016) PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism. Sci Rep 6:19612CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Tanaka M, Yoshida K, Fukagawa M et al (2016) Effects of secondary hyperparathyroidism treatment on improvement in anemia: results from the MBD-5D study. PLoS ONE 11(10):e0164865. CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Friedl C, Reibnegger G, Kramar R (2017) Mortality in dialysis patients with cinacalcet use: a large observational registry study. Eur J Intern Med 42:89–95CrossRefPubMedGoogle Scholar
  31. 31.
    Palmer SC, Stripoli Nistor I et al (2013) Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med 10(4):e1001436CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Ballinger AE, Palmer SC, Nistor I et al (2014) Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev. CrossRefPubMedGoogle Scholar
  33. 33.
    Goldsmith D, Covic A, Vervloet M, Cozzolino M, Nistor I (2015) Chronic Kidney Disease-Mineral Bone Disease (CKD-MBD) working group and the European Renal Best Practice (ERBP) advisory board; should patients with CKD stage 5D and biochemical evidence of secondary hyperparathyroidism be prescribed calcimimetic therapy? An ERA-EDTA position statement. Nephrol Dial Transpl 30(5):698–700CrossRefGoogle Scholar
  34. 34.
    Fassbinder W, Brunner FP et al (1991) Combined report on regular dialysis and transplantation in Europe. Nephrol Dial Transpl 6(Suppl 1):5–35Google Scholar
  35. 35.
    Decker PA, Cohen EP, Ashley ME et al (2001) Subtotal parathyroidectomy in renal failure: still needed after all these years. World J Surg 25:708–712CrossRefPubMedGoogle Scholar
  36. 36.
    Esposito MG, Cesare CM, De Santo RM et al (2008) Parathyroidectomy improves the quality of sleep in maintenance hemodialysis patients with severe hyperparathyroidism. J Nephrol Suppl 13:S92–S96Google Scholar
  37. 37.
    Conzo G, Perna A, Avenia N et al (2012) Evaluation of “putative” role of intraoperative intact parathyroid hormone assay during parathyroidectomy for secondary hyperparathyroidism. A retrospective study on 35 consecutive patients. Endocrine 42(3):606–611CrossRefPubMedGoogle Scholar
  38. 38.
    Bleyer AJ, Burkart J, Piazza M et al (2005) Changes in cardiovascular calcification after parathyroidectomy in patients with ESRD. Am J Kidney Dis 46:464–469CrossRefPubMedGoogle Scholar
  39. 39.
    Goldsmith DJ, Covic AA, Venning MC et al (1996) Blood pressure reduction after parathyroidectomy for secondary hyperparathyroidism: further evidence implicating calcium homeostasis in blood pressure regulation. Am J Kidney Dis 27:819–825CrossRefPubMedGoogle Scholar
  40. 40.
    Evenepoel P, Claes K, Kuypers D et al (2005) Impact of parathyroidectomy on renal graft function, blood pressure and serum lipids in kidney transplant recipients: a single centre study. Nephrol Dial Transpl 20:1714–1720CrossRefGoogle Scholar
  41. 41.
    Stein MS, Packham DK, Wark JD et al (1999) Response to parathyroidectomy at the axial and appendicular skeleton in renal patients. Clin Nephrol 52:172–178PubMedGoogle Scholar
  42. 42.
    Rayes N, Seehofer D, Schindler R et al (2008) Long-term results of subtotal vs total parathyroidectomy without autotransplantation in kidney transplant recipients. Arch Surg 143:756–761CrossRefPubMedGoogle Scholar
  43. 43.
    Jofre R, Lopez Gomez JM, Menarguez J et al (2003) Parathyroidectomy: whom and when? Kidney Int 63(Supplement 85 ):S97–S100CrossRefGoogle Scholar
  44. 44.
    Gupta PK, Smith RB, Gupta H et al (2012) Outcomes after thyroidectomy and parathyroidectomy. Head Neck 34:477–484CrossRefPubMedGoogle Scholar
  45. 45.
    Hsu Y-H, Yu H-I, Kao C-H et al (2016) The risk of peripheral arterial disease after parathyroidectomy in patients with end-stage renal disease. PLoS ONE 11(6):e0156863. CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Ivarsson KM, Akaberi Sh, Isaksson E et al (2015) The effect of parathyroidectomy on patient survival in secondary hyperparathyroidism. Nephrol Dial Transpl 30:2027–2033CrossRefGoogle Scholar
  47. 47.
    Kestenbaum B, Seliger SL, Gillen DL et al (2004) Parathyroidectomy rates among United States dialysis patients: 1990–1999. Kidney Int 65:282–288CrossRefPubMedGoogle Scholar
  48. 48.
    Komaba H, Taniguchi M, Wada A et al (2015) Parathyroidectomy and survival among Japanese hemodialysis patients with secondary hyperparathyroidism. Kidney Int 88:350–359CrossRefPubMedGoogle Scholar
  49. 49.
    Sharma J, Raggi P, Kutner N et al (2012) Improved long-term survival of dialysis patients after near-total parathyroidectomy. J Am Coll Surg 214:400–407CrossRefPubMedPubMedCentralGoogle Scholar
  50. 50.
    Conzo G, Perna A, Savica S et al (2013) Impact of parathyroidectomy on cardiovascular outcomes and survival in chronic hemodialysis patients with secondary hyperparathyroidism. A retrospective study of 50 cases prior to calcimimetics era. BMC Surg 13(Suppl 2):S4. CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Apetrii M, Goldsmith D, Covic A et al (2017) Impact of surgical parathyroidectomy on chronic kidney disease-mineral and bone disorder (CKD-MBD)—a systematic review and meta-analysis. PLoS ONE 12(11):e0187025. CrossRefPubMedPubMedCentralGoogle Scholar
  52. 52.
    van der Plas WY, Dulfer RR, Engelsman AF et al (2017) Effect of parathyroidectomy and cinacalcet on quality of life in patients with end-stage renal disease-related hyperparathyroidism: a systematic review. Nephrol Dial Transpl 32(11):1902–1908CrossRefGoogle Scholar
  53. 53.
    Parfrey PS, Block G, Chertow G et al (2016) Lessons learned from EVOLVE for planning of future randomized trials in patients on dialysis. Clin J Am Soc Nephrol 11(3):539–546CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V., part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Nephrology-DialysisUHC “Mother Teresa”TiranaAlbania
  2. 2.University Department of Nephrology, Medical FacultyUniversity of SkopjeSkopjeMacedonia

Personalised recommendations